DE60216099D1 - Methode zum auffinden von abgeschwächten oder virulent-defekten mikroben - Google Patents

Methode zum auffinden von abgeschwächten oder virulent-defekten mikroben

Info

Publication number
DE60216099D1
DE60216099D1 DE60216099T DE60216099T DE60216099D1 DE 60216099 D1 DE60216099 D1 DE 60216099D1 DE 60216099 T DE60216099 T DE 60216099T DE 60216099 T DE60216099 T DE 60216099T DE 60216099 D1 DE60216099 D1 DE 60216099D1
Authority
DE
Germany
Prior art keywords
virulent
weakened
detecting
identification
microbes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60216099T
Other languages
English (en)
Inventor
Elke Freissler
M Fuchs
S Niesalla
Heiko Apfel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CREATOGEN AG
Original Assignee
CREATOGEN AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CREATOGEN AG filed Critical CREATOGEN AG
Application granted granted Critical
Publication of DE60216099D1 publication Critical patent/DE60216099D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60216099T 2001-05-17 2002-05-17 Methode zum auffinden von abgeschwächten oder virulent-defekten mikroben Expired - Lifetime DE60216099D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01112158 2001-05-17
EP01117866 2001-07-23
PCT/EP2002/005493 WO2002092814A2 (en) 2001-05-17 2002-05-17 Screening method for attenuating or virulence defective microbial cells

Publications (1)

Publication Number Publication Date
DE60216099D1 true DE60216099D1 (de) 2006-12-28

Family

ID=26076587

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60216099T Expired - Lifetime DE60216099D1 (de) 2001-05-17 2002-05-17 Methode zum auffinden von abgeschwächten oder virulent-defekten mikroben

Country Status (5)

Country Link
US (1) US20040152099A1 (de)
EP (1) EP1407014B1 (de)
AT (1) ATE345386T1 (de)
DE (1) DE60216099D1 (de)
WO (1) WO2002092814A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390620B2 (en) 2001-04-06 2008-06-24 Creatogen Laboratories Gmbh Screening method for anti-microbial drug targets by genome-saturating mutagenesis (GSM)
SE0300413D0 (sv) * 2003-02-15 2003-02-15 Innate Pharmaceuticals Ab Sätt att identifiera nya virulensassocierade gener

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764370A (en) * 1984-09-12 1988-08-16 Scripps Clinic And Research Foundation Vaccine utilizing an avirulent strain of Salmonella typhimurium
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
HUT76975A (hu) * 1994-12-09 1998-01-28 Imperial College Innovations Limited Eljárás gének azonosítására
US6139817A (en) * 1996-10-15 2000-10-31 Smithkline Beecham Corporation Method for determining gene essentiality in a pathogen
AU3196099A (en) * 1998-03-27 1999-10-18 President And Fellows Of Harvard College Systematic identification of essential genes by (in vitro) transposon mutagenesis
CA2341349C (en) * 1998-09-04 2013-12-10 Creatogen Aktiengesellschaft Attenuated cells comprising sp12 mutants, carriers and compositions containing same, methods of production and uses thereof
SE9901961D0 (sv) * 1999-05-28 1999-05-28 Anders Folkesson Fimbrial proteins
WO2000073502A2 (de) * 1999-05-31 2000-12-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Essentielle gene und genprodukte zur identifizierung, entwicklung und optimierung von immunologischen und pharmakologischen wirkstoffen zur behandlung mikrobieller infektionen
WO2001002555A1 (en) * 1999-07-06 2001-01-11 Institut Pasteur Method of making and identifying attenuated microorganisms, compositions utilizing the sequences responsible for attenuation, and preparations containing attenuated microorganisms
US7390620B2 (en) * 2001-04-06 2008-06-24 Creatogen Laboratories Gmbh Screening method for anti-microbial drug targets by genome-saturating mutagenesis (GSM)

Also Published As

Publication number Publication date
EP1407014A2 (de) 2004-04-14
US20040152099A1 (en) 2004-08-05
ATE345386T1 (de) 2006-12-15
WO2002092814A3 (en) 2004-01-22
WO2002092814A2 (en) 2002-11-21
EP1407014B1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
MA29075B1 (fr) Enzymes et procedes
AU2003240327A8 (en) Composition and methods for obtaining nucleic acids from sputum
MXPA03002218A (es) Peptidos antimicrobianos y metodos de uso.
EP1590362B8 (de) Verbessertes Verfahren zur Behandlung durch Bisulfit
WO1999034003A3 (en) Proteases from gram positive organisms
WO1999033960A3 (en) Proteases from gram positive organisms
MX2007006610A (es) Metodo para simplificar acidos nucleicos microbianos por modificacion quimica de citosinas.
WO2003004614A3 (en) Identification and use of conserved noncoding sequences
SE0202713D0 (sv) Water purification
ATE452187T1 (de) Methode zur isolation von nukleinsäuren
SE0301951D0 (sv) New method
BR0014663A (pt) Moléculas de ácido nucléico para a detecção de bactérias e unidades filogenéticas de bactérias
DE60216099D1 (de) Methode zum auffinden von abgeschwächten oder virulent-defekten mikroben
KR100750659B1 (ko) 계면활성제 및 산화제에 매우 안정한 호염, 호알카리성 단백질 분해효소 및 이를 암호화하는 유전자
DE60036551D1 (de) VERWENDUNG VON BAKTERIELLEN ParD kis/ParD kid TOXIN-ANTITOXIN SYSTEM ZUR TÖTUNG VON EUKARYOTISCHEN ZELLEN
WO2003106625A3 (en) HAMMER HEAD RIBOZYMES
WO2007084488A3 (en) Adam10 and its uses related to infection
WO2006037102A3 (en) Methods for identifying polymerase inhibitors
PT1383796E (pt) Estirpe neurovirulenta do vírus do nilo ocidental e as suas aplicações
DE60130465D1 (de) Mutierte muskelspezifische enhancer
ATE334209T1 (de) Inaktivierung von genen des mep-wegs
GB2366291A (en) A transformant for screening of inhibitors for human immnodeficiency virus
DE60327182D1 (de) Verfahren zur herstellung von l-aminosäuren unter verwendung von stämmen der familie enterobacteriaceae
WO2000021984A3 (en) Nucleic acids encoding human cide-b protein and polymorphic markers thereof
IL195194A0 (en) Thermostable dna polymerase of the archaeal ampullavirus abv and its applications

Legal Events

Date Code Title Description
8332 No legal effect for de